The Research Works Initiates Coverage of Provectus (OTC BB "PVCT")Equity Research Firm Targets $5.00 Share Price

Provectus Pharmaceuticals, Inc. (OTC Bulletin Board: PVCT) today announced that The Research Works, Inc., an equity research boutique, initiated coverage and published a report on the Company. The report is available online through Stocks on the Web, the web-publishing division of The Research Works, at www.stocksontheweb.com/pvct.htm.

Knoxville, TN (PRWEB) January 19, 2004 --Provectus Pharmaceuticals, Inc. (OTC Bulletin Board: PVCT) today announced that The Research Works, Inc., an equity research boutique, initiated coverage and published a report on the Company. The report is available online through Stocks on the Web, the web-publishing division of The Research Works, at www.stocksontheweb.com/pvct.htm.

Citing Provectus robust pipeline of prescription drug candidates and target markets for its OTC products that exceed $1 billion annually, Analyst William J. Ritger noted, It seems reasonable to set a target price for Provectus stock at $5 per share, with substantial upside potential if the Company hits its operating milestones."

The Research Works was founded in 1982 and provides a variety of high-quality equity research services focused on small-cap and micro-cap companies. Their services are primarily geared towards the sophisticated and self-directed investor.

About Provectus Pharmaceuticals, Inc.
Provectus Pharmaceuticals, Inc. (OTCBB:PVCT) is a pioneering pharmaceutical company actively engaged in the design, development and marketing of a diverse portfolio of leading patented pharmaceutical technologies for the treatment of liver, breast and prostate cancer. In addition, Provectus has developed and patented treatments for skin diseases, psoriasis and a variety of other skin
condition products.

Provectus experienced management team, comprised of several leading scientists, developed and own 12 US patents, and are currently pending approval on 18 patent applications developed through a six-year, $30 million research program in collaboration with Photogen Technologies, (Nasdaq:PHGN).

For more information on Provectus, please visit the Companys web site at www.pvct.com.

Forward-Looking Statements
This release and others statements issued or made from time to time by the company or its representatives contain statements that may constitute forward- looking statements. Those statements include statements regarding the intent, belief or current expectations of the company and members of its management teams as well as the assumptions on which the statements are based. Prospective investors are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements.